Moderna Drops 20% on Cancer Vaccine Data Leak Report — SkimNews
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- Moderna crashed 20% on reports of leaked data from its experimental melanoma vaccine trial, spooking investors and triggering a sharp sell-off in its stock
- Merck saw its shares fall alongside Moderna’s, reflecting market linkage between the two companies due to their joint development of the cancer vaccine candidate
- Moderna is increasingly pivoting from its COVID-19 vaccine business toward oncology, with Wall Street observing a strategic shift despite the current setback
- Moderna outperformed broader market indices on some days even during the downturn, suggesting pockets of investor confidence amid volatility
Why it matters: The 20% drop in Moderna’s stock erases billions in market value overnight, intensifying pressure on its unproven cancer pipeline just as it seeks to redefine itself beyond COVID vaccines. Merck’s decline shows how tightly its fate is tied to trial outcomes it does not solely control.
Ask SkimNews
